Satoshi Tanizaki, Kinnosuke Matsumoto, Akihiro Tamiya, Yoshihiko Taniguchi, Yoshinobu Matsuda, Junji Uchida, Kiyonobu Ueno, Hayato Kawachi, Motohiro Tamiya, Takafumi Yanase, Hidekazu Suzuki, Kyoichi Okishio
OBJECTIVES: Ramucirumab (RAM) and docetaxel (DOC) are commonly used after first-line therapy for advanced non-small cell lung cancer (NSCLC). Therefore, we aimed to elucidate sequencing strategies of RAM and DOC following prior treatments, including immune checkpoint inhibitor (ICI), cytotoxic agent (CTx) alone, bevacizumab (BEV), and tyrosine kinase inhibitor (TKI). METHODS: We recruited patients with NSCLC who received RAM and DOC and compared the groups with and without prior ICI, CTx alone, BEV, and TKI, respectively...
February 11, 2023: European Journal of Clinical Pharmacology